Autosomal-dominant polycystic kidney disease (ADPKD) affects about 1 of every 1,000 persons on earth. Half of affected persons can expect to develop end-stage chronic renal disease (ESRD) during their lifetimes. The condition represents 15% of dialysis populations worldwide. Other affected persons will die prematurely from various cardiovascular causes. The cloning of PKD1 and PKD2 spurred an enormous amount of research into ADPKD. PKD1 encodes polycystin-1, a large transmembrane protein that interacts with polycystin-2, a nonselective calcium channel that localizes to primary cilia in the renal epithelium. PKD2 encodes polycystin-2. Mutations in these two genes make up the vast majority of ADPKD patients. Discovery of these proteins as present in cilia placed ADPKD into the category of the human "ciliopathies", which includes a host of other complex genetic diseases, notably the nephronophtheses, the Bardet-Biedl syndromes, and a dozen other conditions, many of which also feature renal cysts [1] . The cilia proteins responsible for these conditions participate in Wnt signaling, Hedgehog signaling, platelet-derived growth factor (PDGF) signaling, fibroblast growth factor (FGF) signaling, and interact with the mammalian target of rapamicin (mTOR) signaling pathway (Fig. 1) . The ciliary location of PC-1 and PC-2 and the presence of cilia on the luminal surface of renal tubular cells are consistent with the idea that cilia are important for the maintenance of tubular planar cell polarity [2] . Animal models suggested that mTOR inhibitors could ameliorate cyst growth perhaps by assuming the role that mutated PC-1 or PC-2 could not fulfill; however, recent clinical trials were disappointing [3] .
The cells lining renal tubules generally divide parallel to the tubular axis, which lengthens the tubule rather than increasing tubular diameter. A loss of planar cell polarity could be a precursor to cyst formation. Cysts can occur anywhere along the nephron and destroy the kidney. Only a thousand or so cysts are necessary to eventually destroy the kidney, arising from the 1,000,000 or so nephrons in each kidney. The autosomal-dominant inheritance and the fact that the disease affects aging adults rather than children, is consistent with the notion that the second allele is somehow "hit" and rendered nonfunctional.
In German, the word "Gretchenfrage" (literally "Gretchen question") refers to a question aiming at the "core of the issue". Inherent in the Gretchen question is the fact that those supplying the answers make a confession, or at any rate a "difficult decision", to obtain the answer. The core of this issue is, "what is the mechanism of cyst growth?" Cyst growth, as we have learned, destroys the remaining renal parenchyma. The existence of elegant conditional and controllable gene-deleted mouse models has provided additional information.
Repair of acute kidney injury is impaired in mice lacking Pkd1 or Pkd2. The kidneys acquire more dilated tubules than wild-type mice. The knockout in adult mice subjected to acute kidney injury exhibits a sensitivity that is similar to changes observed in juvenile mice. These data suggest that the cystic signal may not necessarily require a "second hit" to become manifest. In addition, acute kidney injury accelerates cyst formation. Conceivably, cyst formation could depend upon the occurrence of either a somatic mutagenesis or an injury event. Either of these events could be construed as a "second hit" that interacts with heterozygosity at one of the ADPKD loci to cause the disease. Nonetheless, the Gretchenfrage remains, "what causes cyst expansion?"
The fluid-filled cysts continue to increase in size, in contrast to the normally compactly arranged tubules in their surroundings [2] . The cyst cells organize themselves in a spherical, rather than a longitudinal structure, and the lumens are filled with increasing amounts of fluid to increase the cyst size. To increase the surface area, the cysts must increase their cell number, rather than merely stretching the epithelial layer of available cells. Therefore, the loss of planar-cell polarity theory receives support since the cells no longer divide according to their long axis. Such evidence supports the importance of planar cell polarity in cyst formation. However, loss of the polarity may not be the sole answer to the key event (Gretchen question) in promoting cyst growth (Fig. 2) .
Somehow, the developing cysts must expand according to the conversion of an ion-absorptive cell to an ion-secretory cell along lines of the cyst lumen. Ion secretion into the cystic lumen must be derived from paracellular or transcellular osmotic water movements into the cyst (Fig. 3) . Such a process is dependent upon chloride transport and requires cyclic adenosine monophosphate (cAMP). The cAMPstimulated fluid movement could involve the cystic fibrosis transmembrane regulator protein (CFTR), a critical chloride channel and the basolateral Na Belibi et al. [3] harvested mural cells from renal cysts derived from patients with ADPKD. They prepared the cells in culture and measured cAMP responses to agonists, transepithelial anion currents, and extracellular signalrelated kinase expression. Belibi et al. [3] were able to show that endogenous adenylyl cyclase agonists promote cell proliferation and electrolyte secretion of human ADPKD and ARPKD cells in vitro. Their evidence further suggested that the cyst-derived cells had their origin in the collecting duct, rather than other tubular sites. The renal collecting duct system possesses two major cell types. The principal cells mediate the collecting duct's influence on sodium and potassium balance via sodium and potassium channels located on the cell's basolateral membrane. [6] showed years ago that MDCK cells, cultured in hydrated-collagen gel, produced polarized monolayered epithelial cysts when intracellular cAMP was increased by prostaglandin E1, vasopressin, cholera toxin, forskolin, or 8-bromoadenosine 3′,5′-cyclic monophosphate. They also observed that 3-isobutyl-1-methylxanthine, a nucleotide phosphodiesterase inhibitor, potentiated all agonists. Furthermore, Mangoo-Karim et al. showed that the cell proliferation component of cyst enlargement was accelerated by cAMP agonists. Chloride levels were higher in the cyst fluid and the secreted fluid than in the bathing medium. Mangoo-Karim et al. concluded that the development of MDCK cysts was dependent on cAMP.
In this issue, Buchholz et al. [7] pursued the importance of collecting duct cells in cyst formation further. They studied MDCK cell subclones. The C7 subclone resembles principal cells, while the C11 subclone resembles intercalated cells. The authors found that cultured cysts developed only from C7-derived clones and not from C11-derived clones. Their findings imply that principal cells are indeed the source of renal cysts. In vitro cyst growth in their model occurred upon elevation of intracellular cAMP and mainly driven by fluid secretion, rather than increased cell proliferation. The cAMP-dependent fluid secretion was found to depend on extracellular ATP and to act synergistically with purinergic signaling, since the ATP scavenger apyrase and the P2Y receptor inhibitor suramin-reduced cAMP-driven fluid secretion, while increasing extracellular ATP potentiated cAMP-mediated cyst growth. These findings are in accord with the earlier report by Turner et al. [6] , who showed that stimulation of endogenous P2Y receptors by extracellular ATP increases growth of MDCK cysts via cAMP-dependent activation of the ERK pathway. They suggested that P2Y receptor antagonists could have therapeutic potential in reducing cyst size and slowing disease progression.
Cystic cells are markedly different from normal collecting duct principal cells, and surely also from MDCK cells. Chloride presumably enters from a basolateral Na (Fig. 3) . The chloride probably mostly exists via the CFTR. Presumably, the chloride transport into the cyst lumen drives sodium and water secretion down transmembrane potential and osmotic gradients. Novel therapies to diminish the growth of cysts, with even less-than dramatic effects, could have a substantial effect on clinical outcomes. Such studies are currently being performed [7] . Two mTOR inhibitor trials have been completed that gave less than the expected result [8] . There are numerous explanations, not the least of which is that treatment is started when the disease is relatively faradvanced, albeit still asymptomatic. V2 receptor antagonist studies are underway. Also in the works are studies involving long-acting somatostatin analogs. Various antihypertensive trials and even sympathectomy is being considered. To my knowledge, no trials of P2Y inhibitors are as yet underway. My interpretation would be that the therapists address the "difficult decision" regarding the Gretchen question. Only direct testing will supply an answer. Suffice it to say, the intense research is surely worth it and help is underway for these patients.
Respectfully, Friedrich C. Luft
